730 Participants Needed

Standard Colonoscopy for Colon Adenomas

(SSL follow-up Trial)

Dv
JF
Overseen ByJulie Fleury
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Standard Colonoscopy for Colon Adenomas?

Standard colonoscopy is highly effective for detecting and treating colon adenomas, which are growths that can lead to cancer. It is considered the best method for finding these growths, and removing them during the procedure can lower the risk of developing colorectal cancer.12345

Is standard colonoscopy generally safe for humans?

Colonoscopy is generally considered a safe procedure with a low rate of major adverse events like bleeding and perforation. However, minor issues such as abdominal pain and infection can occur, and serious events are more common when additional procedures like polypectomy are performed.678910

How does standard colonoscopy differ from other treatments for colon adenomas?

Standard colonoscopy is unique because it is the gold standard for detecting pre-malignant lesions like adenomas, but it can miss some due to limitations in visualizing certain areas of the colon. Unlike other treatments, it involves direct visual examination and removal of polyps, but its effectiveness can be affected by factors like bowel preparation and anatomical challenges.311121314

What is the purpose of this trial?

The primary aim of this study is to determine the rate of total metachronous advanced neoplasia (TMAN) detection after index detection of serrated lesions (SL) \[sessile serrated polyps (SSPs), traditional serrated adenomas (TSAs)\], and metachronous high-risk adenoma (HRA) after index detection of high-grade dysplasia (HGD).We will use the database of patients diagnosed with SL or HGD at index colonoscopy with a delay in surveillance and determine the risk of advanced lesions (especially high-risk lesion and CRC detection) of these delayed colonoscopies. The aim is to determine the effects of breach of continuity of care in these patients.

Research Team

Dv

Daniel von Renteln, Md

Principal Investigator

Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria

This trial is for people aged 45-80 who had a colonoscopy at CHUM between 2009 and 2022, found to have serrated lesions (SL) or high-grade dysplasia (HGD), and are due for follow-up. It's not for those with certain genetic syndromes, inflammatory bowel disease, colorectal cancer at first checkup, short life expectancy, or too early for next colonoscopy.

Inclusion Criteria

I am aged 45-80 and had a colonoscopy at CHUM between 2009-2022 with findings but missed my follow-up.

Exclusion Criteria

Patients with a life expectancy too short to benefit from colonoscopy
I was diagnosed with colorectal cancer during a colonoscopy.
I have been diagnosed with inflammatory bowel disease.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients undergo standard colonoscopy with removal of optically diagnosed polyps for histopathological evaluation

1 day
1 visit (in-person)

Follow-up

Participants are monitored for the rate of metachronous advanced neoplasia detection after index detection of serrated lesions and high-grade dysplasia

1 year
Periodic follow-up visits as per standard clinical follow-up

Long-term Surveillance

Participants may undergo additional follow-up colonoscopies based on surveillance intervals recommended by guidelines

3-10 years

Treatment Details

Interventions

  • Standard Colonoscopy
Trial Overview The study looks at how often high-risk adenomas come back after finding SL or HGD during a standard colonoscopy. Researchers will track details like polyp characteristics and removal success to understand the risk of future serious issues in the colon.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ColonoscopyExperimental Treatment1 Intervention
Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials
389
Recruited
143,000+

Findings from Research

This study is a prospective, multicenter, randomized controlled trial involving 1772 patients to compare the adenoma detection rate between Endocuff Vision™-assisted colonoscopy and standard colonoscopy, aiming to improve the quality of bowel cancer screening.
The trial will provide important insights into the effectiveness of Endocuff Vision™ in enhancing adenoma detection rates, which is crucial for reducing the incidence of interval cancers and improving overall patient outcomes in colonoscopy.
The ADENOMA Study. Accuracy of Detection using Endocuff Vision™ Optimization of Mucosal Abnormalities: study protocol for randomized controlled trial.Bevan, R., Ngu, WS., Saunders, BP., et al.[2022]
Colonoscopy is not only the gold standard for detecting colorectal adenomas but also serves as an effective treatment method, significantly reducing the risk of colorectal cancer.
Various advanced endoscopic resection techniques, such as endoscopic mucosal resection and endoscopic submucosal dissection, are available and are guided by recent recommendations from the European Society of Gastrointestinal Endoscopy.
Endoscopic management of colorectal adenomas.Meier, B., Caca, K., Fischer, A., et al.[2020]
Balloon-assisted colonoscopy significantly improved the detection rate of simulated polyps compared to standard colonoscopy, with a detection rate of 91.7% versus 45.8% in a controlled colon model study involving 50 gastroenterologists.
This technique was particularly effective in identifying both non-obscured and obscured polyps, suggesting it could reduce the adenoma miss rate in real clinical settings, warranting further studies in human participants.
A novel balloon colonoscope detects significantly more simulated polyps than a standard colonoscope in a colon model.Hasan, N., Gross, SA., Gralnek, IM., et al.[2014]

References

The ADENOMA Study. Accuracy of Detection using Endocuff Vision™ Optimization of Mucosal Abnormalities: study protocol for randomized controlled trial. [2022]
Endoscopic management of colorectal adenomas. [2020]
A novel balloon colonoscope detects significantly more simulated polyps than a standard colonoscope in a colon model. [2014]
Endoscopist Adenoma Per Colonoscopy Detection Rates and Risk for Post Colonoscopy Colorectal Cancer: Data From New Hampshire Colonoscopy Registry. [2023]
Advanced colorectal polyp detection techniques. [2021]
ASGE review of adverse events in colonoscopy. [2020]
Adverse events related to colonic endoscopic mucosal resection and polypectomy. [2022]
Colon mucosal injury caused by water jet malfunction during a screening colonoscopy: A case report. [2022]
Colonoscopy adverse events: are we getting the full picture? [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
The incidence of 30-day adverse events after colonoscopy among outpatients in the Netherlands. [2015]
Evaluation of colonoscopy data for colorectal polyps and associated histopathological findings. [2022]
Colonoscopic polypectomy--evaluation of the effectiveness and safety (single center experience). [2019]
13.United Statespubmed.ncbi.nlm.nih.gov
Impact of Inadequate Bowel Cleansing on Colonoscopic Findings in Routine Screening Practice. [2022]
14.United Statespubmed.ncbi.nlm.nih.gov
Impact of proximal colon retroflexion on adenoma miss rates. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security